Abstract. Cognitive impairment (CI) refers to dysfunctional cognition, which encompasses a spectrum of disorders, ranging from mild cognitive impairment to dementia. Any factor that results in cortical damage may cause CI. Total flavonoids of *Selaginella pulvinata* (TFSP), have shown promising antioxidant and protective effects in animal models. In the present study, mice were intraperitoneally treated with scopolamine, sodium nitrite or 45% ethanol to induce memory impairment, and the effects were assessed using a step-down test. After performing the behavioural test, hippocampal sections were collected for anatomical analysis, and the brain and serum levels of memory-related molecules were evaluated. The results showed that TFSP improved memory in a mouse model of CI significantly. Serum data were consistent with the behavioural results: TFSP increased blood acetylcholine levels through modulation of the acetylcholinesterase and choline acetyltransferase levels. It also ameliorated oxidative stress in neurons, increasing superoxide dismutase, glutathione peroxidase and inhibiting nitric oxide synthase levels in the brain. These results suggest that TFSP may exhibit potential as a clinical treatment for neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and senile dementia.

Introduction

Both *Selaginella tamariscina* (Beauv.) and *Selaginella pulvinata* (Hook.et Grev.) are recorded in the Chinese Pharmacopoeia as Juanbai (1), a traditional Chinese herb. Selaginella, described as a 'whorl leaf stonecrop plant', has the ability to recuperate even after a long period of drought (2). According to traditional Chinese medicine, Selaginella is mild-natured, pungent, distributes to the liver and heart meridians, and improves blood circulation. Selaginella has been shown to exhibit antioxidant (3,4), antidiabetic (5,6), anti-tumor (7) and angiogenic properties (8). The primary active components in selaginella are flavonoids, which comprise ~2.85% of the plant matter (9).

The physiological basis of cognitive impairment (CI), also referred to as cognitive deficit or cognitive disability, include aging, shrinkage or degeneration of brain tissue. These processes may result from abnormalities in the levels and actions of neurotransmitters and receptors, aggregation and modification of proteins in brain tissue, chronic cerebral ischemic injuries and diseases that result in insufficient blood supply to the brain (10). In addition, external factors such as infection, poisoning and metabolic dysfunction can lead to CI. CI is most common in individuals >60 years old. If not well controlled, CI will develop into senile dementia.

Models of memory impairment are useful for evaluating the effects of drugs on learning and memory processes. In the present study, memory impairment was induced using scopolamine, sodium nitrite or ethanol. Scopolamine is a competitive muscarinic cholinergic receptor antagonist that impairs memory acquisition (11). Sodium nitrite increases methemoglobin content in the blood, resulting in a lowered carrying capacity of oxygen, thus leading to brain tissue hypoxia, which impairs memory consolidation (12). Ethanol inhibits cortical activity, conditioned reflexes, RNA synthesis and protein synthesis, thereby impairing memory retrieval (13).

Materials and methods

Experimental animals. A total of 200 Kunming male and female mice, weighing 18-22 g, [animal
The following day, testing was conducted; each mouse was down to the electrified floor, it was considered an error. Subsequently, when a mouse descended back down such that both of its feet touched the floor at the same time, it received a shock. Each time a mouse descended down to the electrified floor, it was considered an error. The following day, testing was conducted; each mouse was placed on the platform, and the latency of the first jump as well as number of jumps within a 5-min testing period were recorded.

Total flavonoids of Selaginella pulvinata (TFSP) acute toxicity test. Mice were observed for 3 days prior to testing, and those displaying abnormal appearance or abnormal behavior were excluded from further analysis. In a preliminary test, 6 mice were administered the maximum volume (40 ml/kg) of the maximum concentration (10.5 g/100 ml) of TFSP once, and observed for 14 days; and no deaths occurred. Therefore, this maximal dose was used in an acute toxicity test, in which TFSP was administered by gavage at day 0, and observed for 14 days. Throughout the test, the hair, behavior, autonomic activity, respiration, oral and nasal secretions, diet, urine and time of death of each animal were observed. Animal weights were measured every other day. At the end of the experiment, mice were sacrificed by cervical dislocation, and the internal organs were harvested for examination.

Preparation of TFSP suspension. TFSP was prepared as described previously (14). Briefly, the high-dose suspension (40 mg/ml) was prepared by mixing 2.8 g TFSP powder with 70 ml distilled water. Medium (20 mg/ml) and low (10 mg/ml) doses were then diluted from the high dose suspension by adding distilled water accordingly. The prepared suspensions were stored at 4°C.

Experimental model. Test animals were habituated to the test environment for 3 days before being randomly divided into groups. For each memory impairment model type, there were 5 groups (n=10 per group): control, CI, high-dose TFSP, medium-dose TFSP and low-dose TFSP. The control groups were administered distilled water by gavage and injected intraperitoneally with normal saline. The CI groups were administered distilled water by gavage and injected intraperitoneally with either scopolamine hydrobromide (5 mg/kg) or sodium nitrite (90 mg/kg) or 45% ethanol (10 ml/kg). The TFSP groups were administered with the indicated doses of TFSP suspension via gavage and injected intraperitoneally with either scopolamine hydrobromide (5 mg/kg) or sodium nitrite (90 mg/kg) or 45% ethanol (10 ml/kg). Drugs were administered once a day for 4 weeks.

Step-down test. Mice were placed in the control box of the step-down instrument for 1 min. Then, at the onset of a 5-min training period, a 32 V electric current was applied to the floor. Mice respond by jumping onto the platform to escape the electric shock. Subsequently, when a mouse descended back down such that both of its feet touched the floor at the same time, it received a shock. Each time a mouse descended down to the electrified floor, it was considered an error. The following day, testing was conducted; each mouse was placed on the platform, and the latency of the first jump as well as number of jumps within a 5-min testing period were recorded.

Statistical analysis. All results are presented as mean ± standard deviation. Data were compared across the three groups using a one-way ANOVA with a post-hoc Tukey-Kramer test. P<0.05 was considered to indicate a statistically significant difference.

Results

TFSP acute toxicity test. Of the 20 test mice (10 each male and female) administered the maximum volume (40 ml/kg) of TFSP suspension (10.5 g/100 ml) by gavage daily for 14 days, none died or exhibited abnormal reactions, and no abnormalities were observed in their dissected organs (data not shown). The body weights of the mice increased gradually (Fig. 1). Thus, the experimental doses of TFSP used were 1/5 (800 mg/kg), 1/10 (400 mg/kg) and 1/20 (200 mg/kg) of the maximum dose, all of which were considered to be safe.

Behavioral effects of TFSP on scopolamine model mice. The scopolamine group displayed shorter mean latency to error and a greater mean number of errors compared with the control group (both P<0.001). Mice treated with high and medium doses of TFSP had significantly longer error
latencies and fewer errors compared with those treated with scopolamine alone (P<0.05; Fig. 2). Pathological analysis showed that scopolamine reduced hippocampal neuron counts significantly, and the cells observed were sparsely arranged and disordered (Fig. 3B). These effects were partially reversed in mice brains treated with TFSP (400 and 800 mg/kg; Fig. 3C-E).

Effects of TFSP on cholinergic molecules in brain tissue. Mice treated with scopolamine had lower levels of acetylcholine in the brain compared with the untreated controls. A high-dose of TFSP increased the levels of acetylcholine in the brain (P<0.05; Fig. 4), reduced the activity of the acetylcholinesterase and increased the activity of the acetylcholine-biosynthesizing enzyme choline acetyltransferase (both P<0.05, Fig. 5). Medium and low doses of TFSP did not exert any significant effects.

Behavioral effects of TFSP on mice treated with sodium nitrite. Mice treated with sodium nitrite displayed a significantly shorter mean error latency and a greater mean number of errors compared with the untreated controls (P<0.01; Fig. 6). All TFSP doses prolonged error latency significantly, and the high and medium doses of TFSP reduced the number of errors significantly compared with the model group (P<0.05).

Pathological images of toluidine blue staining showed that mice injected with sodium nitrite had fewer hippocampal neurons, and the cells were sparsely arranged and disordered. Treatment with TFSP appeared to ameliorate these effects (Fig. 7).

Effects of TFSP on MDA content and SOD activity in brain tissue of mice treated with sodium nitrite. Compared with the control group, the MDA content in the brains of CI mice model was increased (P<0.05), and SOD activity was decreased (P<0.01), suggesting that sodium nitrite induced oxidative stress. TFSP significantly reduced MDA content (P<0.05, Fig. 8) and increased SOD activity (800 mg/kg, P<0.01; 400 and 200 mg/kg, P<0.05 Fig. 9).

Effects of TFSP on NO content and NOS activity in brain tissues of mice treated with sodium nitrite. Levels of NO and activity of NOS were higher in the brains of the model mice compared with the untreated controls (P<0.01). High and medium doses of TFSP significantly reduced NO content (P<0.05) and NOS activity (P<0.01; Fig. 10).

Effects of TFSP on GSH content and GSH-Px activity in brain tissues of mice treated with sodium nitrite. Levels of GSH and GSH-Px activity were significantly lower in the brains of the model mice compared with the untreated controls (P<0.01), suggesting that the brain tissues of the model group were in a state of oxidative damage. Treatment with medium and high doses of TFSP increased GSH content (Fig. 11) and GSH-Px activity significantly (Fig. 12).

TFSP improves impairments in memory retrieval induced by ethanol. Both the latency to error and the number of errors were significantly worse in ethanol-treated mice compared with the controls (P<0.001). Compared with the model group, all three TFSP doses significantly prolonged error latency (P<0.01) and reduced the number of errors (P<0.05; Fig. 13).

Discussion

TFSP contributes to the improvement of behavior in mice with memory impairments induced by scopolamine, sodium nitrite.
or 45% ethanol. TFSP treatment increased error latencies and reduced the number of errors in the step-down behavioral test. Furthermore, TFSP appeared to protect against hippocampal damage induced by these treatments as it associated with a reduced loss and disordering of hippocampal cells. These results suggest that TFSP may ameliorate CI at a cellular level.

The content of acetylcholine in brain tissue is closely associated with cognitive function, and is dependent on the relative activities of acetylcholinesterase and choline acetyltransferase. Activated acetylcholinesterase breaks down acetylcholine, whereas activated choline acetyltransferase promotes synthesis of acetylcholine (15). Scopolamine mimics
the memory dysfunction caused by insufficient acetylcholine by blocking muscarinic receptors (16,17). The results of the present study showed that TFSP may exhibit therapeutic effects on scopolamine-induced memory dysfunction via regulation of these key cholinergic enzymes.

Sodium nitrite leads to CI by inducing hypoxia (18), and also contributes to brain damage by disrupting redox reactions and producing large quantities of peroxides and free radicals (such as MDA and NO) (19). The resulting hypoxic environment decreases the activity of antioxidant enzymes, such as...
SOD and GSH-Px, resulting in an accumulation of peroxidation products and free radicals, thereby further aggravating tissue damage. The results of the present study demonstrated
that TFSP promotes favorable regulation of peroxides, free radicals and antioxidant enzymes, supporting the protection and repair of brain tissue, and thus cognition.

NO acts as reactive oxygen, and produces opposing effects on acetylcholine release in neuronal Aplysia synapses, dependent on the excitatory or the inhibitory nature of the synapse (20). In the present study, TFSP reduced NO and acetylcholinesterase levels in the serum and alleviated cognitive dysfunction in a similar manner to benazepril hydrochloride does (21).

Estrogen serves an important role in cognition (22). Flavonoids in Selaginella pulvinata have estrogenic (23,24) and neuroprotective effects (25), that may have contributed to the relief of CI observed in the present study. It may also improve the cholinergic system through its estrogen-like effects, although this requires further study to confirm.

In conclusion, TFSP showed no significant acute toxicity in mice, and exerted a protective effect in several mouse models of CI. TFSP was associated with improvements in both cytological and behavioral measures. These results suggest that TFSP may be a promising treatment for CI. Further investigations on TFSP should focus on the active component(s), and additional mouse models of cognition, such as a maze test should be used to evaluate efficacy, before assessing its suitability in humans.

Acknowledgements

We would like to thank Mr Quancheng Zhao (Jilin Academy of traditional Chinese Medicine), Mrs Xiyan Ou, Mr Xiaobing Li and Mr Yunlu Ding (Chunchun University of Chinese Medicine), Mr Xuefeng Lv (Songyuan Food and Drug Administration) and Mrs Liaping Wang (Xizheng Pharmaceutical Group Co., Ltd.) for their experimental help.

Funding

This study was funded by Sanya Institute and Local Science and Technology Project (grant no. 2019YD11) and Hainan Tropical Ocean University Scientific Research Starting Foundation for PhD (grant no. RHDXB201708).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

LZ conceived the experiments, analyzed the results, and wrote and edited the manuscript. YZ and YH wrote the manuscript, performed the experiments and analyzed the results. HL, CL, JX, NZ, and QL performed the experiments and analyzed the results. YS conceived the experiments and wrote the manuscript. ZZ designed the study, analyzed data and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Animal Care and Welfare Committee of Changchun University of Chinese Medicine (Changchun, China) (approval no. 20120120).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia, 2015. http://db.ouryao.com/yd2015/view.php?v=ttxtkid=353
2. Nanjing University of Chinese Medicine. Great Dictionary of Chinese Medicine, 2006.
3. Zheng XK, Wang WW, Zhang L, Su CF, Wu YY, Ke YY, Hou QW, Liu ZY, Guo AS and Feng WS: Antihyperlipidaemic and antidepressive effect of the total flavonoids in Selaginella tamariscina (Beauv.) Spring in diabetic mice. J Pharm Pharmacol 65: 757-766, 2013.
4. Zhang Z, Sun T, Niu JG, He ZQ, Liu Y and Wang F: Amentoflavone protects hippocampal neurons: Anti-inflammatory, antioxidative, and antiapoptotic effects. Neural Regen Res 10: 1125-1133, 2015.
5. Su C, Yang C, Gong M, Ke Y, Yuan P, Wang X, Li M, Zheng X and Feng W: Antiabetic activity and potential mechanism of amentoflavone in diabetic mice. Molecules 24: E2184, 2019.
6. Zheng X, Ke Y, Feng A, Yuan P, Zhou Y, Yu Y, Wang X and Feng W: The Mechanism by which amentoflavone improves insulin resistance in HepG2 cells. Molecules 21: pii: E624, 2016.
7. Yang JS, Lin CW, Hsieh YS, Cheng HL, Lue KH, Yang SF and Lu KH: Selaginella tamariscina (Beauv.) possesses antimetastatic effects on human osteosarcoma cells by decreasing MMP-2 and MMP-9 secretions via p38 and Akt signaling pathways. Food Chem Toxicol 59: 801-807, 2013.
8. Zheng XK, Ning TL, Wang XL, Liu CX, Liu YY and Feng WS: Effects of total flavonoids and amentoflavone isolated from Selaginella tamariscina on human umbilical vein endothelial cells proliferation and VEGF expression. J Chin Pharm Sci 46: 998-1002, 2011.
9. Yan Y, Zhu HY, Ma L: Content determination of flavones in five genus of Selaginella from Guizhou province, China. J Yunnan Univ (Natural Science Edition) 32: 227-231, 2010.
10. Experts group of prophylaxis and treatment cognitive impairment in China. Expert consensus on prevention and treatment of cognitive impairment in China. Chinese Journal of Internal Medicine 45: 171-173, 2006.
11. Klinkenberg I and Blokland A: The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev 8: 1307-1350, 2010.
12. Vohra BP and Hui X: Improvement of impaired memory in mice by taurine. Neural Plast 4: 245-259, 2000.
13. Haab Latte A, Huppes Majolo J, Reali Nazario L and Da Silva RS: Early exposure to ethanol is able to affect the memory of adult zebrafish: Possible role of adenosine. Neurotoxicology 69: 17-22, 2018.
14. Li QJ, Wang LS and Wang LP: Study on Extraction method of total flavonoids from Selaginella tamariscina (Beauv.) Spring. J Changchun Univ Trad Chin Med 28: 355-356, 2012.
15. Park D, Yang YH, Bae DK, Lee SH, Yang G, Kyung J, Kim D, Choi EK, Lee SW, Kim GH, et al: Improvement of cognitive function and physical activity of aging mice by human neural stem cells over-expressing choline acetyltransferase. Neurobiol Aging 34: 2639-2646, 2013.
16. Li B, Guo DY and Li L: Behavioral Comparison among three animal models mimicking Alzheimer’s disease. Chi J Exp Anim 7: 40-45, 1999.
17. Xu JM and Yu HY: Impact of different dosage scopalamine on rat learning and mnemonic ability. J Suzhou Univ (Health Sciences) 26: 53-54, 2006.
18. Zhai ZL, Yan Y, Shang YZ: Improving effects of brevisvapine on chemicals-induced memory impairment in mice. Chin J Biochem Pharm 33: 61-63, 2012.
19. Liu XX, Zhao YY, Chen Chun S and Bai J. Effects of extract of Alpinia officinarum Hance on learning memory consolidation and free radical in mice. Chin Traditional Pat Med 32: 1105-1108, 2010.
20. Mothet JP, Fossier P, Tauc L and Baux G: Opposite actions of nitric oxide on cholinergic synapses: Which pathways? Proc Natl Acad Sci USA 93: 8721-8726, 1996. https://pubmed.ncbi.nlm.nih.gov/?term=Opposite+actions+of+nitric+oxide+on+cholinergic+synapses%3A+Which+pathways%3F

21. Zhao Z, Zhao X and Xu J: The effects of benazepril hydrochloride on nitric oxide, acetylcholine in serum and cerebrospinal fluid of vascular dementia. Shanxi Med J 4: 457-460, 2019. https://xueshu.baidu.com/usercenter/paper/show?paperid=1p6k0lj0v46xf0vx0ad6b06d06q344386&site=xueshu_sc or http://d.wanfangdata.com.cn/periodical/sxyyzz201904021

22. Krolick KN, Zhu Q and Shi H: Effects of estrogens on central nervous system neurotransmission: Implications for sex differences in mental disorders. Prog Mol Biol Transl Sci 160: 105-171, 2018.

23. Zheng XK, Zhang X, Wang XL, Zhang N, Yuan PP and Feng WS: Effect of estrogen-like effective part of Selaginella tamariscina on bone metabolism in ovariectomized rats. Zhong Yao Cai 10: 1826-1829, 2014 (In Chinese).

24. Zheng XK, Jiang Y, Pei SJ, Wang XL, Zhang N, Ke YY, Zhai YY and Feng WS: Experimental study on estrogenic activity of ten kinds of Selaginella tamariscina from ten different place of origin. Xian Dai Zhong Yi Yao 1: 238-242, 2015.

25. Choi RC, Zhu JT, Yung AW, Lee PS, Xu SL, Guo AJ, Zhu KY, Dong TT and Tsim KW: Synergistic action of flavonoids, baicalin, and daidzein in estrogenic and neuroprotective effects: A development of potential health products and therapeutic drugs against Alzheimer's disease. Evid Based Complement Alternat Med 2013: 635694, 2013.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.